Advertisement

Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma

Published:March 29, 2013DOI:https://doi.org/10.1016/j.jss.2013.03.023

      Abstract

      Background

      Severe injury and associated hemorrhagic shock lead to an inflammatory response and subsequent increased tissue damage. Numerous reports have shown that injury-induced inflammation and the associated end-organ damage is driven by Toll-like receptor 4 (TLR4) activation via damage-associated molecular patterns. We examined the effectiveness of Eritoran tetrasodium (E5564), an inhibitor of TLR4 function, in reducing inflammation induced during hemorrhagic shock with resuscitation (HS/R) or after peripheral tissue injury (bilateral femur fracture, BFF).

      Material and methods

      Mice underwent HS/R or BFF with or without injection of Eritoran (5 mg/kg body weight) or vehicle control given before, both before and after, or only after HS/R or BFF. Mice were sacrificed after 6 h and plasma and tissue cytokines, liver damage (histology; aspartate aminotransferase/alanine aminotransferase), and inflammation (NF-κB) and gut permeability were assessed.

      Results

      In HS/R Eritoran significantly reduced liver damage (values ± SEM: alanine aminotransferase 9910 ± 3680 U/L versus 1239 ± 327 U/L and aspartate aminotransferase 5863 ± 2000 U/L versus 1246 ± 243 U/L, P < 0.01) at 6 h compared with control when given just before HS and again just prior to resuscitation. Eritoran administration also led to lower IL-6 levels in plasma and liver and less NF-κB activation in liver. Increases in gut barrier permeability induced by HS/R were also prevented with Eritoran. Eritoran similarly diminished BFF-mediated systemic inflammatory responses.

      Conclusion

      These data suggest Eritoran can inhibit tissue damage and inflammation induced via TLR4/myeloid differentiation factor 2 signaling from damage-associated molecular patterns released during HS/R or BFF. Eritoran may represent a promising therapeutic for trauma patients to prevent multiple organ failure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. WISQARS. National Center for Injury Prevention and Control. Center for Disease Control and Prevention 2007. 2007. 9–3-2011.Ref Type: Online Source. Available from: http://www.cdc.gov/injury/wisqars/index.html.

        • Levy R.M.
        • Prince J.M.
        • Yang R.
        • et al.
        Systemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4.
        Am J Physiol Regul Integr Comp Physiol. 2006; 291: R970
        • Prince J.M.
        • Levy R.M.
        • Yang R.
        • et al.
        Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock.
        J Am Coll Surg. 2006; 202: 407
        • Fan J.
        TLR cross-talk mechanism of hemorrhagic shock-primed pulmonary neutrophil infiltration.
        Open Crit Care Med J. 2010; 2: 1
        • Mollen K.P.
        • Levy R.M.
        • Prince J.M.
        • et al.
        Systemic inflammation and end organ damage following trauma involves functional TLR4 signaling in both bone marrow-derived cells and parenchymal cells.
        J Leukoc Biol. 2008; 83: 80
        • Barsness K.A.
        • Arcaroli J.
        • Harken A.H.
        • et al.
        Hemorrhage-induced acute lung injury is TLR-4 dependent.
        Am J Physiol Regul Integr Comp Physiol. 2004; 287: R592
        • Chen H.
        • Koustova E.
        • Shults C.
        • Sailhamer E.A.
        • Alam H.B.
        Differential effect of resuscitation on Toll-like receptors in a model of hemorrhagic shock without a septic challenge.
        Resuscitation. 2007; 74: 526
        • Reino D.C.
        • Pisarenko V.
        • Palange D.
        • et al.
        Trauma hemorrhagic shock-induced lung injury involves a gut-lymph-induced TLR4 pathway in mice.
        PLoS One. 2011; 6: e14829
        • McGhan L.J.
        • Jaroszewski D.E.
        The role of toll-like receptor-4 in the development of multi-organ failure following traumatic haemorrhagic shock and resuscitation.
        Injury. 2012; 43: 129
        • Park B.S.
        • Song D.H.
        • Kim H.M.
        • Choi B.S.
        • Lee H.
        • Lee J.O.
        The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.
        Nature. 2009; 458: 1191
        • DeMarco M.L.
        • Woods R.J.
        From agonist to antagonist: structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins.
        Mol Immunol. 2011; 49: 124
        • Akira S.
        • Takeda K.
        Toll-like receptor signalling.
        Nat Rev Immunol. 2004; 4: 499
        • Levy R.M.
        • Mollen K.P.
        • Prince J.M.
        • et al.
        Systemic inflammation and remote organ injury following trauma require HMGB1.
        Am J Physiol Regul Integr Comp Physiol. 2007; 293: R1538
        • Montminy S.W.
        • Khan N.
        • McGrath S.
        • et al.
        Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response.
        Nat Immunol. 2006; 7: 1066
        • Mullarkey M.
        • Rose J.R.
        • Bristol J.
        • et al.
        Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
        J Pharmacol Exp Ther. 2003; 304: 1093
        • Bennett-Guerrero E.
        • Grocott H.P.
        • Levy J.H.
        • et al.
        A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
        Anesth Analg. 2007; 104: 378
        • Liu M.
        • Gu M.
        • Xu D.
        • Lv Q.
        • Zhang W.
        • Wu Y.
        Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury.
        Transpl Proc. 2010; 42: 1539
        • Shimamoto A.
        • Chong A.J.
        • Yada M.
        • et al.
        Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.
        Circulation. 2006; 114: I270
        • Gill R.
        • Ruan X.
        • Menzel C.J.
        • et al.
        Systemic inflammation and liver injury following hemorrhagic shock and peripheral tissue trauma involve functional TLR9 signaling on bone marrow-derived cells and parenchymal cells.
        Shock. 2011; 35: 164
        • Kawa K.
        • Tsutsui H.
        • Uchiyama R.
        • et al.
        IFN-gamma is a master regulator of endotoxin shock syndrome in mice primed with heat-killed Propionibacterium acnes.
        Int Immunol. 2010; 22: 157
        • Kobbe P.
        • Kaczorowski D.J.
        • Vodovotz Y.
        • et al.
        Local exposure of bone components to injured soft tissue induces Toll-like receptor 4-dependent systemic inflammation with acute lung injury.
        Shock. 2008; 30: 686
        • Korff S.
        • Falsafi R.
        • Czerny C.
        • et al.
        Time dependency and topography of hepatic NF-kappaB activation after hemorrhagic shock and resuscitation in mice.
        Shock. 2012; 38: 486
        • Yang R.
        • Gallo D.J.
        • Baust J.J.
        • et al.
        Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock.
        Am J Physiol Gastrointest Liver Physiol. 2002; 283: G212
        • Luyer M.D.
        • Buurman W.A.
        • Hadfoune M.
        • et al.
        Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-alpha and preserves gut barrier function early after hemorrhagic shock.
        Shock. 2004; 21: 65
        • Fan J.
        • Li Y.
        • Vodovotz Y.
        • Billiar T.R.
        • Wilson M.A.
        Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation.
        Am J Physiol Lung Cell Mol Physiol. 2006; 290: L738
        • Mollen K.P.
        • Anand R.J.
        • Tsung A.
        • Prince J.M.
        • Levy R.M.
        • Billiar T.R.
        Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage.
        Shock. 2006; 26: 430
        • Tsung A.
        • Klune J.R.
        • Zhang X.
        • et al.
        HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling.
        J Exp Med. 2007; 204: 2913
        • Powers K.A.
        • Szaszi K.
        • Khadaroo R.G.
        • et al.
        Oxidative stress generated by hemorrhagic shock recruits Toll-like receptor 4 to the plasma membrane in macrophages.
        J Exp Med. 2006; 203: 1951
        • Fan J.
        • Li Y.
        • Vodovotz Y.
        • Billiar T.R.
        • Wilson M.A.
        Neutrophil NAD(P)H oxidase is required for hemorrhagic shock-enhanced TLR2 up-regulation in alveolar macrophages in response to LPS.
        Shock. 2007; 28: 213
        • Ehrentraut S.
        • Lohner R.
        • Schwederski M.
        • et al.
        In vivo toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
        Shock. 2011; 36: 613
        • Tidswell M.
        • Tillis W.
        • LaRosa S.P.
        • et al.
        Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
        Crit Care Med. 2010; 38: 72
        • Barochia A.
        • Solomon S.
        • Cui X.
        • Natanson C.
        • Eichacker P.Q.
        Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
        Expert Opin Drug Metab Toxicol. 2011; 7: 479
        • Wong Y.N.
        • Rossignol D.
        • Rose J.R.
        • Kao R.
        • Carter A.
        • Lynn M.
        Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.
        J Clin Pharmacol. 2003; 43: 735